Lista de obras - David Jamieson - Dominio Público Uruguay

A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells

artículo científico publicado en 2019

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

artículo científico publicado en 2016

Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo

artículo científico publicado en 2012

Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability

artículo científico publicado en 2016

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma

artículo científico publicado en 2016

Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers

scientific article published on 25 November 2019

Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma.

artículo científico publicado en 2009

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

artículo científico publicado en 2017

Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial

artículo científico publicado en 2020

Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer

artículo científico publicado en 2016

High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers

artículo científico publicado en 2015

Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.

artículo científico publicado en 2014

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

artículo científico publicado en 2016

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

artículo científico publicado en 2010

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

artículo científico publicado en 2018

Institutional profile: pharmacogenomics research at Newcastle University.

artículo científico publicado en 2012

Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation.

artículo científico publicado en 2011

NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism

artículo científico publicado en 2007

Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?

artículo científico publicado en 2017

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.

artículo científico publicado en 2016

Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil

artículo científico publicado en 2014

Pharmacogenetics of genes across the doxorubicin pathway.

artículo científico publicado en 2011

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

artículo científico publicado en 2016

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

artículo científico publicado en 2016

Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor

artículo científico publicado en 2006

Temporary Single-Cell Coating for Bioprocessing with a Cationic Polymer

artículo científico publicado en 2017

The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide

artículo científico publicado en 2011

Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy

artículo científico publicado en 2011

Lista de obras de David Jamieson

A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo

Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma

Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers

Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial

Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer

High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers

Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

Institutional profile: pharmacogenomics research at Newcastle University.

Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation.

NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism

Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.

Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil

Pharmacogenetics of genes across the doxorubicin pathway.

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor

Temporary Single-Cell Coating for Bioprocessing with a Cationic Polymer

The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide

Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy